ORAL PREPARATION FOR PROMOTING EXPRESSION OF TGF-BETA, ORAL PREPARATION FOR INHIBITING PRODUCTION OF PAIN-MEDIATING SUBSTANCE, AND ORAL PREPARATION FOR PREVENTING EDEMA
An oral preparation for promoting expression of TGF-β includes as an active ingredient hyaluronic acid or a pharmaceutically acceptable salt thereof, the oral preparation promoting expression of TGF-β in plasma. In addition, an oral preparation for suppressing production of a pain-producing substance includes as an active ingredient hyaluronic acid or a pharmaceutically acceptable salt thereof, the oral preparation suppressing production of a pain-producing substance by promoting expression of TGF-β in plasma. In addition, an oral preparation for suppressing production of a pain-producing substance includes as an active ingredient hyaluronic acid or a pharmaceutically acceptable salt thereof, the oral preparation suppressing production of a pain-producing substance PGE2 and/or bradykinin. In addition, an oral preparation for suppressing edema includes as an active ingredient hyaluronic acid or a pharmaceutically acceptable salt thereof, the oral preparation suppressing production of a pain-producing substance PGE2 and/or bradykinin.
